Recursion Pharmaceuticals (RXRX) Cash from Investing Activities Growth (1y) (2021 - 2026)
Recursion Pharmaceuticals (RXRX) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.60 Bn | 944.55 Mn | -6.02 Mn | 95.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.35% |
| Dec 31, 2025 | -100.45% |
| Sep 30, 2025 | 44.13% |
| Jun 30, 2025 | -38.88% |
| Mar 31, 2025 | -9.27% |
| Dec 31, 2024 | 11,171.38% |
| Sep 30, 2024 | -1,214.70% |
| Jun 30, 2024 | -103.70% |
| Mar 31, 2024 | -24.59% |
| Dec 31, 2023 | 68.82% |
| Sep 30, 2023 | -100.65% |
| Jun 30, 2023 | -141.56% |
| Mar 31, 2023 | -103.73% |
| Dec 31, 2022 | 84.73% |
| Sep 30, 2022 | 127.33% |
| Jun 30, 2022 | 179.52% |
| Mar 31, 2022 | 838.07% |
| Dec 31, 2021 | -1,037.94% |
| Sep 30, 2021 | -5,558.87% |
| Jun 30, 2021 | -15,828.21% |